drugset / Trial / NCT06396585
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer
Timeline
- Start
- 2024-08-01
- Primary completion
- 2025-08-31
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Tegafur | Unknown | 40 mg/m2 | — |
| Subject | Tegafur | Unknown | 60 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |